Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV

Antiviral Drugs: From Basic Discovery through Clinical Trials

Volumn , Issue , 2011, Pages 317-328

  Lin, Kai ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

HCV inhibitory activities, cyclosporin analogs and cyclophilin binding affinities; NIM811, and HCV patient care NIM811 and IFN , in vitro using HCV replicon system; Other HCV inhibitors, cyclophilin inhibitor NIM811 discovery novel therapeutic agent for HCV

Indexed keywords

EID: 84885972070     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470929353.ch22     Document Type: Chapter

References (58)

1. Wang, P.; Heitman, J. The cyclophilins. Genome Biol. 2005, 6(7), 226.
2. Handschumacher, R. E.; Harding, M. W.; Rice, J.; Drugge, R. J.; Speicher, D.W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984, 226(4674), 544-547.
3. Fischer, G.; Bang, H.; Mech, C. Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides.] Biomed. Biochim. Acta 1984, 43(10), 1101-1111.
4. Fischer, G.; Wittmann-Liebold, B.; Lang, K.; Kiefhaber, T.; Schmid, F. X. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 1989, 337(6206), 476-478.
5. Takahashi, N.; Hayano, T.; Suzuki, M. Peptidyl-prolyl cistrans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989, 337(6206), 473-475.
6. Zydowsky, L. D.; Etzkorn, F. A.; Chang, H. Y.; Ferguson, S. B.; Stolz, L. A.; Ho, S. I.; Walsh, C. T. Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporinAbinding and calcineurin inhibition. Protein Sci. 1992, 1(9), 1092-1099.
7. Inoue, K.; Sekiyama, K.; Yamada, M.; Watanabe, T.; Yasuda, H.;Yoshiba,M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J. Gastroenterol. 2003, 38(6), 567-572.
8. Rosenwirth, B.; Billich, A.; Datema, R.; Donatsch, P.; Hammerschmid, F.; Harrison, R.; Hiestand, P.; Jaksche, H.; Mayer, P.; Peichl, P. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob. Agents Chemother. 1994, 38(8), 1763-1772.
9. Billich, A.; Hammerschmid, F.; Peichl, P.;Wenger, R.; Zenke, G.; Quesniaux, V.; Rosenwirth, B. Mode of action of SDZ NIM811, a nonimmunosuppressive cyclosporinAanalogwith activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J. Virol. 1995, 69(4), 2451-2461.
10. Damaso, C. R.; Keller, S. J. Cyclosporin A inhibits vaccinia virus replication in vitro. Arch. Virol. 1994, 134(3-4), 303-319.
11. Karpas, A.; Lowdell, M.; Jacobson, S. K.; Hill, F. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. Proc. Natl. Acad. Sci. USA 1992, 89(17), 8351-8355.
12. Vahlne,A.; Larsson, P. A.;Horal, P.; Ahlmen, J.; Svennerholm, B.; Gronowitz, J. S.; Olofsson, S. Inhibition of herpes simplex virus production in vitro by cyclosporin A. Arch. Virol. 1992, 122( 1-2), 61-75.
13. Bose, S.; Mathur, M.; Bates, P.; Joshi, N.; Banerjee, A. K. Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype. J. Gen. Virol. 2003, 84(Pt. 7), 1687-1699.
14. Bouchard, M. J.; Puro, R. J.; Wang, L.; Schneider, R. J. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J. Virol. 2003, 77(14), 7713-7719.
15. Watashi, K.; Hijikata, M.; Hosaka, M.; Yamaji, M.; Shimotohno, K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003, 38(5), 1282-1288.
16. Nakagawa, M.; Sakamoto, N.; Enomoto, N.; Tanabe, Y.; Kanazawa, N.; Koyama, T.; Kurosaki, M.; Maekawa, S.; Yamashiro, T.; Chen, C. H.; et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem. Biophys. Res. Commun. 2004, 313(1), 42-47.
17. Ma, S.; Boerner, J. E.; TiongYip, C.; Weidmann, B.; Ryder, N. S.; Cooreman, M. P.; Lin, K. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob. Agents Chemother. 2006, 50(9), 2976-2982.
18. Watashi, K.; Ishii, N.; Hijikata, M.; Inoue, D.; Murata, T.; Miyanari, Y.; Shimotohno, K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell 2005, 19(1), 111-122.
19. Heck, J. A.; Meng, X.; Frick, D. N. Cyclophilin B stimulates RNAsynthesis by theHCVRNAdependentRNApolymerase. Biochem. Pharmacol. 2009, 77(7), 1173-1180.
20. Yang, F.; Robotham, J. M.; Nelson, H. B.; Irsigler, A.; Kenworthy, R.; Tang, H. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J. Virol. 2008, 82(11), 5269-5278.
21. Chatterji, U.; Bobardt, M.; Selvarajah, S.; Yang, F.; Tang, H.; Sakamoto, N.; Vuagniaux, G.; Parkinson, T.; Gallay, P. The isomerase active site of cyclophilin a is critical for HCV replication. J. Biol. Chem. 2009, 284(25), 16998-17005.
22. Liu, Z.; Yang, F.; Robotham, J. M.; Tang, H. A Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the HCV replication complex. J. Virol. 2009, 83(13), 6554-6555.
23. Robida, J. M.; Nelson, H. B.; Liu, Z.; Tang, H. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J. Virol. 2007, 81(11), 5829-5840.
24. Fernandes, F.; Poole, D. S.;Hoover, S.;Middleton, R.;Andrei, A. C.; Gerstner, J.; Striker, R. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology 2007, 46(4), 1026-1033.
25. Hanoulle, X.; Badillo, A.; Wieruszeski, J. M.; Verdegem, D.; Landrieu, I.; Bartenschlager, R.; Penin, F.; Lippens,G.Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J. Biol. Chem. 2009, 284(20), 13589-13601.
26. Nakagawa, M.; Sakamoto, N.; Tanabe, Y.; Koyama, T.; Itsui, Y.; Takeda, Y.; Chen, C. H.; Kakinuma, S.; Oooka, S.; Maekawa, S.; et al. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005, 129(3), 1031-1041.
27. Wiedmann, B.; Puyang, X.;Brown,A.; Gaither,A.; Baryza, J.; Boerner, J. E.; Poulin,D.; Ma, S.; Shen,X.; Tao, J.; et al. Roles of cyclophilins in HCV replication and mode of action of the cyclophilin inhibitor NIM811. 14th International Symposium on Hepatitis C Virus and Related Viruses, 2007.
28. Traber, R.; Kobel, H.; Loosli, H. R.; Senn, H.; Rosenwirth, B.; Lawen, A. [Melle( [4])]cyclosporin, a novel natural cyclosporine with anti-HIV activity: structural elucidation, biosynthesis. Antiviral Chem. Chemother. 1994, 5(5), 331-339.
29. Liu, J.; Farmer, J. D., Jr.; Lane, W. S.; Friedman, J.; Weissman, I.; Schreiber, S. L. Calcineurin is a common target of cyclophilin-cyclosporinAand FKBP-FK506 complexes. Cell 1991, 66(4), 807-815.
30. Jain, J.; McCaffrey, P. G.;Miner, Z.;Kerppola, T. K.; Lambert, J. N.; Verdine, G. L.; Curran, T.; Rao, A. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 1993, 365(6444), 352-355.
31. McCaffrey, P. G.; Luo, C.; Kerppola, T. K.; Jain, J.; Badalian, T. M.; Ho, A. M.; Burgeon, E.; Lane, W. S.; Lambert, J. N.; Curran, T. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. Science 1993, 262(5134), 750-754.
32. Huai, Q.; Kim, H. Y.; Liu, Y.; Zhao, Y.; Mondragon, A.; Liu, J. O.; Ke, H. Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc. Natl. Acad. Sci. USA 2002, 99(19), 12037-12042.
33. Jin, L.; Harrison, S. C. Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc. Natl. Acad. Sci. USA 2002, 99(21), 13522-13526.
34. Kallen, J.; Mikol, V.; Taylor, P.; Walkinshaw, M. D. Xray structures and analysis of 11 cyclosporin derivatives complexed with cyclophilin A. J. Mol. Biol. 1998, 283(2), 435-449.
35. Lee, L.V.;Vickers, C. S.;Wiedmann, B.; Fujimoto, R.;Whitehead, L.; Lin, K.; Ryder, N. S.; Compton, T.; Evans, T. G.; Deng, G. Investigation of mechanism of action of NIM811 by surface plasma resonance, fluorescence polarization, and calcineurin assays. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2008.
36. Rosenwirth, B.; Billich, A.; Datema, R.; Donatsch, P.; Hammerschmid, F.; Harrison, R.; Hiestand, P.; Jaksche, H.; Mayer, P.; Peichl, P. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob. Agents Chemother. 1994, 38(8), 1763-1772.
37. Franke, E. K.; Yuan, H. E.; Luban, J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994, 372(6504), 359-362.
38. Luban, J.; Bossolt, K. L.; Franke, E. K.; Kalpana, G. V.; Goff, S. P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993, 73(6), 1067-1078.
39. Thali, M.; Bukovsky, A.; Kondo, E.; Rosenwirth, B.; Walsh, C. T.; Sodroski, J.; Gottlinger, H. G. Functional association of cyclophilin A with HIV-1 virions. Nature 1994, 372(6504), 363-365.
40. Mlynar, E.; Bevec, D.; Billich, A.; Rosenwirth, B.; Steinkasserer, A. The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells. J. Gen. Virol. 1997, 78(Pt. 4), 825-835.
41. Zhu, Q.; Oei, Y.; Mendel, D. B.; Garrett, E. N.; Patawaran,M. B.; Hollenbach, P. W.; Aukerman, S. L.; Weiner, A. J. Novel robust hepatitis C virus mouse efficacy model. Antimicrob. Agents Chemother. 2006, 50(10), 3260-3268.
42. Prichard, M. N.; Shipman, C., Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14( 4-5), 181-205.
43. Pierra, C.; Amador, A.; Benzaria, S.; Cretton-Scott, E.; D'Amours, M.; Mao, J.; Mathieu, S.; Moussa, A.; Bridges, E. G.; Standring, D. N.; et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. J. Med. Chem. 2006, 49(22), 6614-6620.
44. Chan, L.; Pereira, O.; Reddy, T. J.; Das, S. K.; Poisson, C.; Courchesne, M.; Proulx, M.; Siddiqui, A.; Yannopoulos, C. G.;Nguyen-Ba,N.; et al.Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication: 2. tertiary amides. Bioorg. Med. Chem. Lett. 2004, 14(3), 797-800.
45. Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bos, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426(6963), 186-189.
46. Wiedmann, B.; Puyang, X.; Poulin, D.; Mathy, J. E.; Ma, S.; Anderson, L. J.; Fujimoto, R.; Compton, T.; Lin, K. Characterization of mechanism of resistance to cyclophilin inhibitors in HCV replicon. 15th International Symposium on Hepatitis C Virus and Related Viruses, 2008.
47. Coelmont, L.; Paeshuyse, J.; Kaptein, S.; Vliegen, I.; Kaul, A.; De, C. E.; Rosenwirth, B.; Crabbe, R.; Bartenschlager, R.; Dumont, J. M.; Neyts, J. The cyclophilin inhibitor Debio-025 is a potent inhibitor of hepatitis C virus replication in vitro and has a unique resistance profile. 14th International Symposium on Hepatitis C Virus and Related Viruses, 2007.
48. Mathy, J. E.; Ma, S.; Compton, T.; Lin, K. Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob. Agents Chemother. 2008, 52(9), 3267-3275.
49. Sivaraja, M.; Pouliot, J.; Zhang, J.; Mathy, J. E.; Chenail, G.; Ma, S.; Deng, G.; Chopra, R.; Latour, D.; Fung, K.; et al. In vitro biochemical and virological characterization of GL60667 (LDI133), a potent nonnucleoside inhibitor of the HCV NS5B polymerase. 15th International Symposium on Hepatitis C Virus and Related Viruses, 2008.
50. Traber, R.; Hofmann, H.; Loosli, H. R.; Ponelle, M.; Von Wartburg, A. Neue Cyclosporine aus Tolypocladium inflatum: Die Cyclosporine K-Z. Helv. Chim. Acta 1987, 70, 13-36.
51. Schmidt, B.; Riesner, D.; Lawen, A.; Kleinkauf, H. Cyclosporin synthetase is a 1.4 MDa multienzyme polypeptide: re-evaluation of the molecular mass of various peptide synthetases. FEBS Lett. 1992, 307(3), 355-360.
52. Lawen,A.; Zocher, R. Cyclosporin synthetase. The most complex peptide synthesizing multienzyme polypeptide so far described. J. Biol. Chem. 1990, 265(19), 11355-11360.
53. Weber, G.; Schorgendorfer, K.; Schneider-Scherzer, E.; Leitner, E. The peptide synthetase catalyzing cyclosporine production in Tolypocladium niveum is encoded by a giant 45.8-kilobase open reading frame. Curr. Genet. 1994, 26(2), 120-125.
54. Ke, J.; Lawitz E.; Rozier, R.; Marbury, T.; Nguyen, T.; Serra, D.; Dole, K.; Praestgaard, J.; Huang, M.; Evans, T. Safety and tolerability of NIM811, a novel cyclophilin inhibitor for HCV, following single and multiple acending doses in healthy volunteers and HCV-infected patients. 44th Annual Meeting of the European Association for the Study of the Liver. 2009.
55. Flisiak, R.; Horban, A.; Gallay, P.; Bobardt, M.; Selvarajah, S.; Wiercinska-Drapalo, A.; Siwak, E.; Cielniak, I.; Higersberger, J.; Kierkus, J.; et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology, 2008, 47(3), 817-826.
56. Flisiak, R.; Feinman, S. V.; Jablkowski, M.; Horban, A.; Kryczka, W.; Pawlowska, M.; Heathcote, J. E.; Mazzella, G.; Vandelli, C.; Nicolas-Metral, V.; et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatmentnaive hepatitis C patients. Hepatology, 2009, 49(5), 1460-1468.
57. Hopkins, S.; Heuman, D.; Gavis, E.; Lalezari, J.; Glutzer, E.; DiMassimo, B.; Rusnak, P.; Wring, S.; Smitley, C.; Ribeill, Y. Safety, plasma pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection. 44th Annual Meeting of the European Association for the Study of the Liver, 2009.
58. Gane, E. J.; Roberts, S. K.; Stedman, C.;Angus, P.W.; Ritchie, B.; Elston, R.; Ipe, D.; Baher, L.; Morcos, P.; Najera, I.; et al. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1. 44th Annual Meeting of the European Association for the Study of the Liver, 2009.